# US 11,998,561 B2 · Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,998,561 B2 - Document ID: US11998561B2 - Status: Granted - Kind: B2 - Application number: 17/580,999 - Filed: 2022-01-21 - Published: 2022-05-12 - Granted: 2024-06-04 - Earliest claimed: 2016-08-22 - Assignees: Elysium Health, Inc. - Applicants: Elysium Health, Inc. - Inventors: Eric Alexander Marcotulli; Daniel Antonio Alminana - Web page: https://patentgrep.com/patent/US11998561B2 ## CPC - A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom - A61K 31/09: having two or more such linkages - A61P 25/16: Anti-Parkinson drugs - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Compositions containing a combination of nicotinamide riboside and pterostilbene for treating neurodegenerative disorders, and methods of treating neurodegenerative disorders using these compositions and their equivalents are described. The neurodegenerative disorders that can be treated using these compositions or methods can include Parkinson's disease, Huntington's disease, Alzheimer's disease, and the like. In an embodiment, the compositions containing a combination of nicotinamide riboside and pterostilbene can be prepared as oral formulations. In some embodiments, a dietary supplement comprises nicotinamide riboside and/or pterostilbene or equivalents. ## Claims ### Claim 1 A method of reducing the prevalence of indicia of a neurodegenerative disease in a subject in need thereof comprising administering to the subject a composition consisting of nicotinamide riboside, pterostilbene and a pharmaceutically acceptable carrier and/or excipient, wherein the composition is administered to the subject daily, and the daily dose of nicotinamide riboside is at least 100 mg and the daily dose of pterostilbene is at least 25 mg. ### Claim 2 (depends on 1) The method of claim 1, wherein the daily dose of nicotinamide riboside between 100 and 1500 mg. ### Claim 3 (depends on 1) The method of claim 1, wherein the daily dose of nicotinamide riboside between 100 and 1000 mg. ### Claim 4 (depends on 1) The method of claim 1, wherein the daily dose of nicotinamide riboside between 1000 and 1500 mg. ### Claim 5 (depends on 1) The method of claim 1, wherein the daily dose of pterostilbene is between 25 and 250 mg. ### Claim 6 (depends on 1) The method of claim 1, wherein the daily dose of pterostilbene is between 25 and 500 mg. ### Claim 7 (depends on 1) The method of claim 1, wherein the daily dose of pterostilbene is between 30 and 225 mg. ### Claim 8 (depends on 1) The method of claim 1, wherein the daily dose of pterostilbene is between 40 and 200 mg. ### Claim 9 (depends on 1) The method of claim 1, wherein the daily dose of pterostilbene is between 45 and 250 mg. ### Claim 10 (depends on 1) The method of claim 1, wherein the daily dose of pterostilbene is between 25 and 1000 mg. ### Claim 11 (depends on 1) The method of claim 1, wherein the indicia of a neurodegenerative disease are tremors, resting tremors, bradykinesia, NAD+ content, sirtuin activity, limb rigidity, Lewy bodies, postural instability, freezing of gait, micrographia, reduced facial expression, uncontrolled movements, movement that is abnormally fast or slow, stooped posture, dystonia, impaired fine motor dexterity, impaired motor coordination, impaired gross motor coordination, decreased arm swing, akathisia, speech problems, softness of voice or slurred speech, difficulty swallowing, sexual dysfunction, cramping, drooling, excess saliva, loss of sense of smell, constipation, rapid eye movement (REM) behavior disorder, mood disorder, orthostatic hypotension, sleep disturbances, vision problems, fatigue, loss of energy, depression, memory issues, slowed thinking, confusion, death of dopaminergic neurons, reduced dopamine concentration, prion occurrence, or dementia. ### Claim 12 (depends on 1) The method of claim 1, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, or Huntington's disease. ### Claim 13 (depends on 1) The method of claim 1, wherein the administration of the composition comprises administering one or more daily doses of the composition. ### Claim 14 (depends on 1) The method of claim 1, wherein two or more, thirty or more, fifty or more, or one hundred or more daily doses of the composition are administered. ### Claim 15 (depends on 1) The method of claim 1, wherein the daily doses are administered for at least 7 days, at least 30 days, at least 60 days, at least 90 days, or at least six months. ### Claim 16 (depends on 1) The method of claim 1, wherein the composition is formulated as a pill, a tablet, or a capsule. ### Claim 17 (depends on 1) The method of claim 1, wherein the composition is administered orally. ### Claim 18 (depends on 1) The method of claim 1, wherein the composition is self-administered. ### Claim 19 A method of reducing the prevalence of indicia of a neurodegenerative disease in a subject in need thereof comprising administering to the subject a composition consisting of nicotinamide riboside, pterostilbene and a pharmaceutically acceptable carrier or excipient, wherein the composition is administered to the subject daily, and the daily dose of nicotinamide riboside is 1000 mg and the daily dose of pterostilbene is 200 mg.